Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

A humanized mouse model identifies key amino acids for low immunogenicity of H7N9 vaccines.

Wada Y, Nithichanon A, Nobusawa E, Moise L, Martin WD, Yamamoto N, Terahara K, Hagiwara H, Odagiri T, Tashiro M, Lertmemongkolchai G, Takeyama H, De Groot AS, Ato M, Takahashi Y.

Sci Rep. 2017 Apr 28;7(1):1283. doi: 10.1038/s41598-017-01372-5.

2.

A(H1N1)pdm09 influenza infection: vaccine inefficiency.

Friedman N, Drori Y, Pando R, Glatman-Freedman A, Sefty H, Bassal R, Stein Y, Shohat T, Mendelson E, Hindiyeh M, Mandelboim M.

Oncotarget. 2017 May 16;8(20):32856-32863. doi: 10.18632/oncotarget.16459.

3.

Influenza and Memory T Cells: How to Awake the Force.

Spitaels J, Roose K, Saelens X.

Vaccines (Basel). 2016 Oct 13;4(4). pii: E33. Review.

4.

Topical CpG Oligodeoxynucleotide Adjuvant Enhances the Adaptive Immune Response against Influenza A Infections.

Cheng WK, Plumb AW, Lai JC, Abraham N, Dutz JP.

Front Immunol. 2016 Jul 29;7:284. doi: 10.3389/fimmu.2016.00284. eCollection 2016.

5.

Clinical characteristics and factors associated with severe acute respiratory infection and influenza among children in Jingzhou, China.

Huai Y, Guan X, Liu S, Uyeki TM, Jiang H, Klena J, Huang J, Chen M, Peng Y, Yang H, Luo J, Zheng J, Peng Z, Huo X, Xiao L, Chen H, Zhang Y, Xing X, Feng L, Hu DJ, Yu H, Zhan F, Varma JK.

Influenza Other Respir Viruses. 2017 Mar;11(2):148-156. doi: 10.1111/irv.12419. Epub 2016 Sep 20.

6.

Heterogeneous and Dynamic Prevalence of Asymptomatic Influenza Virus Infections.

Furuya-Kanamori L, Cox M, Milinovich GJ, Magalhaes RJ, Mackay IM, Yakob L.

Emerg Infect Dis. 2016 Jun;22(6):1052-6. doi: 10.3201/eid2206.151080.

7.

Avian influenza viruses that cause highly virulent infections in humans exhibit distinct replicative properties in contrast to human H1N1 viruses.

Simon PF, de La Vega MA, Paradis É, Mendoza E, Coombs KM, Kobasa D, Beauchemin CA.

Sci Rep. 2016 Apr 15;6:24154. doi: 10.1038/srep24154.

8.

Using the Ferret as an Animal Model for Investigating Influenza Antiviral Effectiveness.

Oh DY, Hurt AC.

Front Microbiol. 2016 Feb 4;7:80. doi: 10.3389/fmicb.2016.00080. eCollection 2016. Review.

9.

Vaccine-preventable infections in Systemic Lupus Erythematosus.

Murdaca G, Orsi A, Spanò F, Faccio V, Puppo F, Durando P, Icardi G, Ansaldi F.

Hum Vaccin Immunother. 2016 Mar 3;12(3):632-43. doi: 10.1080/21645515.2015.1107685.

10.

Production of H5N1 Influenza Virus Matrix Protein 2 Ectodomain Protein Bodies in Tobacco Plants and in Insect Cells as a Candidate Universal Influenza Vaccine.

Mbewana S, Mortimer E, Pêra FF, Hitzeroth II, Rybicki EP.

Front Bioeng Biotechnol. 2015 Dec 8;3:197. doi: 10.3389/fbioe.2015.00197. eCollection 2015.

11.

In Silico Identification of Highly Conserved Epitopes of Influenza A H1N1, H2N2, H3N2, and H5N1 with Diagnostic and Vaccination Potential.

Muñoz-Medina JE, Sánchez-Vallejo CJ, Méndez-Tenorio A, Monroy-Muñoz IE, Angeles-Martínez J, Santos Coy-Arechavaleta A, Santacruz-Tinoco CE, González-Ibarra J, Anguiano-Hernández YM, González-Bonilla CR, Ramón-Gallegos E, Díaz-Quiñonez JA.

Biomed Res Int. 2015;2015:813047. doi: 10.1155/2015/813047. Epub 2015 Aug 6.

12.

Mismatching between circulating strains and vaccine strains of influenza: Effect on Hajj pilgrims from both hemispheres.

Alfelali M, Khandaker G, Booy R, Rashid H.

Hum Vaccin Immunother. 2016 Mar 3;12(3):709-15. doi: 10.1080/21645515.2015.1085144.

13.

Generation of a variety of stable Influenza A reporter viruses by genetic engineering of the NS gene segment.

Reuther P, Göpfert K, Dudek AH, Heiner M, Herold S, Schwemmle M.

Sci Rep. 2015 Jun 12;5:11346. doi: 10.1038/srep11346.

14.

Competitive detection of influenza neutralizing antibodies using a novel bivalent fluorescence-based microneutralization assay (BiFMA).

Baker SF, Nogales A, Santiago FW, Topham DJ, Martínez-Sobrido L.

Vaccine. 2015 Jul 9;33(30):3562-70. doi: 10.1016/j.vaccine.2015.05.049. Epub 2015 Jun 1.

15.

Technical guidelines for the application of seasonal influenza vaccine in China (2014-2015).

Feng L, Yang P, Zhang T, Yang J, Fu C, Qin Y, Zhang Y, Ma C, Liu Z, Wang Q, Zhao G, Yu H.

Hum Vaccin Immunother. 2015;11(8):2077-101. doi: 10.1080/21645515.2015.1027470.

16.

Potential recombinant vaccine against influenza A virus based on M2e displayed on nodaviral capsid nanoparticles.

Yong CY, Yeap SK, Ho KL, Omar AR, Tan WS.

Int J Nanomedicine. 2015 Apr 2;10:2751-63. doi: 10.2147/IJN.S77405. eCollection 2015.

17.

RIG-I and TLR3 are both required for maximum interferon induction by influenza virus in human lung alveolar epithelial cells.

Wu W, Zhang W, Duggan ES, Booth JL, Zou MH, Metcalf JP.

Virology. 2015 Aug;482:181-8. doi: 10.1016/j.virol.2015.03.048. Epub 2015 Apr 11.

18.

A novel video tracking method to evaluate the effect of influenza infection and antiviral treatment on ferret activity.

Oh DY, Barr IG, Hurt AC.

PLoS One. 2015 Mar 4;10(3):e0118780. doi: 10.1371/journal.pone.0118780. eCollection 2015.

19.

Pneumonia and influenza, and respiratory and circulatory hospital admissions in Belgium: a retrospective database study.

Crott R, Pouplier I, Roch I, Chen YC, Closon MC.

Arch Public Health. 2014 Sep 14;72(1):33. doi: 10.1186/2049-3258-72-33. eCollection 2014.

20.

Age-specific differences in influenza virus type and subtype distribution in the 2012/2013 season in 12 European countries.

Beauté J, Zucs P, Korsun N, Bragstad K, Enouf V, Kossyvakis A, Griškevičius A, Olinger CM, Meijer A, Guiomar R, Prosenc K, Staroňová E, Delgado C, Brytting M, Broberg E; European Influenza Surveillance Network.

Epidemiol Infect. 2015 Oct;143(14):2950-8. doi: 10.1017/S0950268814003422. Epub 2015 Feb 4.

Supplemental Content

Support Center